

29 May 2024

Acquisition of CDIs by related parties of UBI

Universal Biosensors, Inc. (ASX: UBI) announces the following:

- 275,000 CDIs were acquired by its Chairman, Graham McLean. Appendix 3Y for this acquisition is attached;
- 1,421 293 CDIs were acquired by Viburnum Funds Pty Ltd, an entity associated with Craig Coleman, a non-executive director of UBI (Appendix 3Y for this transaction was filed on 28 May 2024); and
- 275,000 CDIs were acquired by an associate of John Sharman, CEO of UBI, on 27 May 2024.

End

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.

For further information contact:

Salesh Balak
Company Secretary
+61 (0) 414 508 852

About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Universal Biosensors, Inc.
ARBN: 121 559 993

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Graham McLean
Date of last notice	9 May 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Milray Enterprises Pty Ltd ATF Graham McLean Family Trust of which Graham McLean is a member
Date of change	27 May 2024
No. of securities held prior to change	805,116 CDIs
Class	Shares of common stock traded in the form of CDIs
Number acquired	275,000 CDIs
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$30,250.00
No. of securities held after change	1,080,116 CDIs

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade
---	-----------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.